Triglotix®: Innovative Endotracheal Tube Design Reduces Postoperative Laryngeal Injury

Sponsor
University Hospital of the Nuestra Señora de Candelaria (Other)
Overall Status
Active, not recruiting
CT.gov ID
NCT06108271
Collaborator
(none)
68
1
2
1.5
46

Study Details

Study Description

Brief Summary

The goal of this randomized clinical trial is to compare two different orotracheal tubes in patients which require orotracheal intubation for general anesthesia. The main questions it aims to answer are:

  • To assess the presence of laryngeal injury

  • To evaluate the consequences in voice quality

  • To ask for the presence of symptoms as sore throat, hoarseness, and cough

Participants will be randomly assigned into two groups, one will use conventional endotracheal tube and the other will use Triglotix® endotracheal tube.

Condition or Disease Intervention/Treatment Phase
  • Device: Triglotix®
  • Device: Conventional endotracheal tube
N/A

Detailed Description

Endotracheal intubation is necessary in some patients undergoing surgical procedures and patients requiring mechanical ventilation in the intensive care unit. However, endotracheal intubation is associated with known complications. In post-surgical patients subjected to orotracheal intubation, the incidence of dysphagia, sore throat, hoarseness and cough is 43%,38%27%,32% respectivelly. These figures increase in cases of prolonged intubation, such as those in intensive care units, where reported rates are 76% for sore throat, 63% for hoarseness and 49% for dysphagia. No significant endotracheal tube design improvements have been developed over the past few decades addressing these issues.

The present study aims to compare the incidence of laryngeal injuries, and related symptoms as sore throat, hoarseness, swallowing problems, bucking and coughing between two defined sample populations: those utilizing a conventional endotracheal tube (ETT-C) and those employing the new Triglotix® endotracheal tube (ETT-T) in patients undergoing elective surgery requiring general anesthesia and mechanical ventilation.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
68 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose:
Prevention
Official Title:
Innovative Endotracheal Tube Design Reduces Postoperative Laryngeal Injury
Actual Study Start Date :
Oct 1, 2023
Anticipated Primary Completion Date :
Nov 1, 2023
Anticipated Study Completion Date :
Nov 15, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: ETT-T

Endotracheal tube Triglotix®

Device: Triglotix®
The Triglotix® has a biocompatible self-expanding viscoelastic cuff that is located in the supraglottic, glottic and subglottic space. This cuff separates the endotracheal tube from the laryngeal vestibule in the supraglottic space and the vocal cords avoiding direct tissue damage from the plastic components of the tube. The viscoelastic cuff self-expands after the endotracheal tube is in adequate position in the airway. Then it adapts progressively and gradually to the shape of structures it comes in contact with, applying minimal pressure to the surrounding tissue. The ETT-T also has two wire reinforced segments: the first is located outside the mouth to prevent deformation related with kinking, while the second segment is positioned distally along the larynx. The primary purpose of this design is to mitigate torsional, rotational and lateralization forces that the tube may encounter while the patient is intubated.
Other Names:
  • ETT-T
  • Active Comparator: ETT-C

    Endotracheal tube conventional

    Device: Conventional endotracheal tube
    Conventional endotracheal tube that is currently used worldwide
    Other Names:
  • ETT-C
  • Outcome Measures

    Primary Outcome Measures

    1. Laryngeal injury [Immediately before the induction and 45 minutes after the end of the procedure]

      Laryngeal pathology was assessed based on the location (unilateral: right/left or bilateral) and on morphology: grade 0 = no lesions, grade 1 = superficial erythema (redness of the mucosa without surrounding inflammation), grade 2 = oedema (swollen mucosa at the vocal cords), grade 3 haematoma (redness of the mucosa with surrounding inflammatory swelling), grade 4 = mucosal laceration (causing active bleeding into the vocal cords), grade 5 = arytenoid dislocation or subluxation (arytenoid with limited movement), and grade 6 = vocal cord palsy

    Secondary Outcome Measures

    1. Postoperative cough [45 minutes after the end of the procedure]

      Postoperative cough was assessed: (0 = None, 1 = mild cough, 2 = moderate cough <5 s, 3 = Severe cough >5 s)

    2. Bucking during extubation [During extubation]

      Presence of bucking during extubation assessed by the anesthesiologist just after stimulating the patient (1 = mild, 2 = severe, 3 = abscense)

    3. Acoustic Voice Quality Index 03.01 (AVQIv3) [Immediately before the induction and 45 minutes after the end of the procedure]

      Concatenated voice samples of 3 seconds of sv [a:] and voiced segments of a phonetically balanced text.

    4. Acoustic Breathiness Index (ABI) [Immediately before the induction and 45 minutes after the end of the procedure]

      Concatenated voice samples of 3 seconds of sv [a:] and voiced segments of a phonetically balanced text.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 70 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    • Elective perianal surgery requiring intubation for general anesthesia

    • Duration range 30-90 minutes

    Exclusion Criteria:
    • Difficult airway

    • American Society of Anesthesiologists physical status (ASA) > III

    • Morbid obesity (body mass index >40 kg/m2)

    • Patients not suitable for outpatient surgery

    • Patients with history of previous neck surgery

    • Patients with history of dysphagia

    • Patients with comorbidities as diabetes and hypertension.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Pedro Luis Bravo Santa Cruz De Tenerife Spain 38001

    Sponsors and Collaborators

    • University Hospital of the Nuestra Señora de Candelaria

    Investigators

    • Principal Investigator: Pedro Bravo, MD, University Hospital of the Nuestra Señora de Candelaria

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    Pedro Luis Bravo, Director, University Hospital of the Nuestra Señora de Candelaria
    ClinicalTrials.gov Identifier:
    NCT06108271
    Other Study ID Numbers:
    • Endotracheal tube Triglotix®
    First Posted:
    Oct 30, 2023
    Last Update Posted:
    Oct 30, 2023
    Last Verified:
    Oct 1, 2023
    Individual Participant Data (IPD) Sharing Statement:
    Yes
    Plan to Share IPD:
    Yes
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Pedro Luis Bravo, Director, University Hospital of the Nuestra Señora de Candelaria
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Oct 30, 2023